A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Meeting Abstract
| Authors: | Chung, C. H.; Colevas, A. D. D.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; Worden, F. P.; Dunn, L.; Seiwert, T. Y.; Jotte, R. M.; Bauman, J. E.; Chaney, M. F.; Margossian, S.; Levisetti, M.; Pai, S. I. |
| Abstract Title: | A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.6013 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 6013 -- This meeting was also held virtually -- Source: Cinahl |
